Recently, Fujifilm announced the start of clinical trials of Avigan in Japan and overseas as one of the drug candidates for COVID-19. In addition, the Japanese government plans to stockpile two m treatment courses* of Avigan, as part of the Japanese government's emergency economic package.
On the back of the efforts to fight against COVID-19 pandemic, CMIC group supports the phase III clinical trial at CMIC Co., Ltd., a pioneer CRO in Japan.
Also, CMIC CMO Co., Ltd., a leading CDMO in Japan, will manufacture "Avigan Tablet" at their main plant to contribute that FUJIFILM Corp. accelerates the production.
CMIC group will continue to show our strong supports to pharmaceutical companies and medical professionals and contribute to the medical care and health of people suffering from COVID-19.
By using our unique business model "Pharmaceutical Value Creator " which covers the value chain of pharmaceutical companies, CMIC group will work to contribute to providing COVID-19 related services below.
Avigan Tablet was approved for manufacture and sale in Japan in 2014 as an influenza antiviral drug for novel or re-emerging influenza virus infections. Japanese government has a certain stock pile of the drug as a countermeasure against such influenza viruses.
CMIC Group was founded in 1992 as the first CRO in Japan.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical